PMID- 1262474
OWN - NLM
STAT- MEDLINE
DCOM- 19760706
LR  - 20181113
IS  - 0021-9738 (Print)
IS  - 0021-9738 (Linking)
VI  - 57
IP  - 5
DP  - 1976 May
TI  - Detection of anti-DNA antibody using synthetic antigens. Characterization and 
      clinical significance of binding of poly (deoxyadenylate-deoxythymidylate) by 
      serum.
PG  - 1330-41
AB  - Virtually all preparations of DNA used to detect antibody to native DNA (nDNA) by 
      binding assays have been found to be subtly contaminated by single stranded DNA. 
      Because recent DNA binding data have directly challenged the unique role 
      previously attributed to these antibodies in systemic lupus erythematosus (SLE), 
      resolution of the consequent ambiguity is of theoretical and practical 
      importance. It is proposed that a synthetic nDNA molecule (dAT) might circumvent 
      this difficulty by being antigenically equivalent to nDNA while, on theoretical 
      grounds, lacking significant contamination with single stranded DNA or other 
      cellular antigens. These expectations were generally confirmed by biochemical and 
      immunological analyses. In clinical studies, sera from 124 pateints with SLE and 
      from controls were examined for their ability to bind dAT. In contrast to results 
      with KB binding, patients with non-SLE rheumatologic disorders were 
      indistinguishable from normals by dAT binding. dAT binding was elevated in 85% of 
      sera from SLE patients with clinically-judged active nephritis but in only 9% of 
      those with inactive renal disease. Active non-renal disease, including 
      cerebritis, was not associated with increased dAT binding. Individual non-lupus 
      sera which bound increased amounts of KB DNA, failed to bind dAT. It is suggested 
      that such binding resulted from contaminating non-nDNA antigens. When elevated, 
      dAT binding, like KB binding, varied with disease activity and might thus be 
      useful as a parameter thereof. In several patients elevated dAT binding led to 
      the finding, on biopsy, of clinically silent, active, diffuse proliferative 
      nephritis. It is concluded that use of synthetic nDNA antigens such as dAT may 
      offer theoretical and practical advantages over naturally-derived preparations in 
      detecting anti-nDNA, both clinically and for investigational purposes. Also, 
      caution is urged in interpreting DNA binding data derived from incompletely 
      characterized systems, particularly with regard to the occurrence of anti-nDNA 
      antibodies in serum.
FAU - Steinman, C R
AU  - Steinman CR
FAU - Deesomchok, U
AU  - Deesomchok U
FAU - Spiera, H
AU  - Spiera H
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Clin Invest
JT  - The Journal of clinical investigation
JID - 7802877
RN  - 0 (Antigens)
RN  - 0 (DNA, Single-Stranded)
RN  - 0 (Polydeoxyribonucleotides)
RN  - 9007-49-2 (DNA)
SB  - IM
MH  - Adult
MH  - Antigen-Antibody Reactions
MH  - *Antigens
MH  - Binding Sites
MH  - Blood
MH  - Cell Line
MH  - DNA/blood/*immunology
MH  - DNA, Single-Stranded/immunology
MH  - Female
MH  - Humans
MH  - Immunoelectrophoresis
MH  - Kinetics
MH  - Nephritis/immunology
MH  - Polydeoxyribonucleotides/*immunology
PMC - PMC436786
EDAT- 1976/05/01 00:00
MHDA- 1976/05/01 00:01
PMCR- 1976/05/01
CRDT- 1976/05/01 00:00
PHST- 1976/05/01 00:00 [pubmed]
PHST- 1976/05/01 00:01 [medline]
PHST- 1976/05/01 00:00 [entrez]
PHST- 1976/05/01 00:00 [pmc-release]
AID - 10.1172/JCI108401 [doi]
PST - ppublish
SO  - J Clin Invest. 1976 May;57(5):1330-41. doi: 10.1172/JCI108401.